Literature DB >> 33402485

Predictors for Grip Strength Loss in Patients With Chronic Liver Diseases.

Hiroki Nishikawa1,2, Kazunori Yoh3, Hirayuki Enomoto3, Naoto Ikeda3, Tomoyuki Takashima3, Nobuhiro Aizawa3, Takashi Nishimura3, Shuhei Nishiguchi4, Hiroko Iijima3.   

Abstract

BACKGROUND/AIM: To elucidate factors associated with secular changes of grip strength (GS) in patients with chronic liver diseases (CLDs) (n=241, 102 males, median age=63 years, 87 liver cirrhosis cases).
MATERIALS AND METHODS: ΔGS (kg/year) was defined as [GS value (second time) - GS value (first time)]/[time interval between the first and second time]. GS loss (GSL) was defined as ΔGS <0 kg/year.
RESULTS: The median ΔGS in patients with non-LC, Child-Pugh A (n=70) and Child-Pugh B (n=17) were 0.3, -0.2 and -1.6 kg/year (overall p<0.0001). In the multivariate analysis of factors linked to the GSL for all cases, extracellular water (ECW) to total body water (TBW) ratio was significant (p=0.0007). In the multivariate analysis in male, no significant factor was found, while in female, ECW to TBW ratio was significant (p=0.0024).
CONCLUSION: Liver functional parameters can be closely linked to the GSL especially in female CLD patients. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Chronic liver disease; grip strength loss; liver function; secular change

Mesh:

Substances:

Year:  2021        PMID: 33402485      PMCID: PMC7880795          DOI: 10.21873/invivo.12267

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  40 in total

1.  Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma.

Authors:  Naoto Fujiwara; Hayato Nakagawa; Yotaro Kudo; Ryosuke Tateishi; Masataka Taguri; Takeyuki Watadani; Ryo Nakagomi; Mayuko Kondo; Takuma Nakatsuka; Tatsuya Minami; Masaya Sato; Koji Uchino; Kenichiro Enooku; Yuji Kondo; Yoshinari Asaoka; Yasuo Tanaka; Kuni Ohtomo; Shuichiro Shiina; Kazuhiko Koike
Journal:  J Hepatol       Date:  2015-02-24       Impact factor: 25.083

Review 2.  Hand-grip dynamometry predicts future outcomes in aging adults.

Authors:  Richard W Bohannon
Journal:  J Geriatr Phys Ther       Date:  2008       Impact factor: 3.381

Review 3.  Frailty, Sarcopenia, and Malnutrition in Cirrhotic Patients.

Authors:  Elizabeth S Aby; Sammy Saab
Journal:  Clin Liver Dis       Date:  2019-08-21       Impact factor: 6.126

4.  Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria.

Authors:  Hiroki Nishikawa; Makoto Shiraki; Akira Hiramatsu; Kyoji Moriya; Keisuke Hino; Shuhei Nishiguchi
Journal:  Hepatol Res       Date:  2016-09       Impact factor: 4.288

Review 5.  Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis.

Authors:  Chalermrat Bunchorntavakul; K Rajender Reddy
Journal:  Aliment Pharmacol Ther       Date:  2019-11-08       Impact factor: 8.171

6.  Reduced handgrip strength is predictive of poor survival among patients with liver cirrhosis: A sex-stratified analysis.

Authors:  Tatsunori Hanai; Makoto Shiraki; Kenji Imai; Atsushi Suetsugu; Koji Takai; Hisataka Moriwaki; Masahito Shimizu
Journal:  Hepatol Res       Date:  2019-10-09       Impact factor: 4.288

Review 7.  What is dynapenia?

Authors:  Brian C Clark; Todd M Manini
Journal:  Nutrition       Date:  2012-05       Impact factor: 4.008

8.  Prognostic significance of low skeletal muscle mass compared with protein-energy malnutrition in liver cirrhosis.

Authors:  Hiroki Nishikawa; Hirayuki Enomoto; Akio Ishii; Yoshinori Iwata; Yuho Miyamoto; Noriko Ishii; Yukihisa Yuri; Ryo Takata; Kunihiro Hasegawa; Chikage Nakano; Takashi Nishimura; Kazunori Yoh; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Hepatol Res       Date:  2017-01-17       Impact factor: 4.288

9.  Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update.

Authors:  Norihiro Kokudo; Nobuyuki Takemura; Kiyoshi Hasegawa; Tadatoshi Takayama; Shoji Kubo; Mitsuo Shimada; Hiroaki Nagano; Etsuro Hatano; Namiki Izumi; Shuichi Kaneko; Masatoshi Kudo; Hiroko Iijima; Takuya Genda; Ryosuke Tateishi; Takuji Torimura; Hiroshi Igaki; Satoshi Kobayashi; Hideyuki Sakurai; Takamichi Murakami; Takeyuki Watadani; Yutaka Matsuyama
Journal:  Hepatol Res       Date:  2019-09-06       Impact factor: 4.288

10.  Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis.

Authors:  Aldo J Montano-Loza; Paul Angulo; Judith Meza-Junco; Carla M M Prado; Michael B Sawyer; Crystal Beaumont; Nina Esfandiari; Mang Ma; Vickie E Baracos
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-06-09       Impact factor: 12.910

View more
  2 in total

1.  Clinical Significance of Serum Zinc Levels on the Development of Sarcopenia in Cirrhotic Patients.

Authors:  Koji Murata; Tadashi Namisaki; Yuki Fujimoto; Soichi Takeda; Masahide Enomoto; Hiroaki Takaya; Yuki Tsuji; Akihiko Shibamoto; Junya Suzuki; Takahiro Kubo; Satoshi Iwai; Fumimasa Tomooka; Misako Tanaka; Miki Kaneko; Shohei Asada; Aritoshi Koizumi; Nobuyuki Yorioka; Takuya Matsuda; Takahiro Ozutsumi; Koji Ishida; Hiroyuki Ogawa; Hirotetsu Takagi; Yukihisa Fujinaga; Masanori Furukawa; Yasuhiko Sawada; Norihisa Nishimura; Koh Kitagawa; Shinya Sato; Kosuke Kaji; Takashi Inoue; Kiyoshi Asada; Hideto Kawaratani; Kei Moriya; Takemi Akahane; Akira Mitoro; Hitoshi Yoshiji
Journal:  Cancer Diagn Progn       Date:  2022-03-03

2.  Possible Alterations in Appetite-related Molecules After the Elimination of Hepatitis C Virus.

Authors:  Yoshihiro Shimono; Hirayuki Enomoto; Nobuhiro Aizawa; Tomoyuki Takashima; Naoto Ikeda; Yukihisa Yuri; Aoi Fujiwara; Kohei Yoshihara; Ryota Yoshioka; Shoki Kawata; Shogo Ota; Ryota Nakano; Hideyuki Shiomi; Takashi Nishimura; Hiroko Iijima
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.